MYELODYSPLASTIC SYNDROME (MDS)
Clinical trials for MYELODYSPLASTIC SYNDROME (MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME (MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug ADCT-301 tested in just 3 patients for relapsed blood cancers
Disease control TerminatedThis study tested a drug called ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer came back after a stem cell transplant. The goal was to see if the drug is safe and can help patients achieve remission. The study was stopped earl…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Gwynn Long, M.D. • Aim: Disease control
Last updated May 17, 2026 03:15 UTC
-
New combo therapy for MDS shows promise in early trial
Disease control TerminatedThis study tested a new drug called sabatolimab added to standard chemotherapy for people with a bone marrow disorder called myelodysplastic syndrome (MDS) at intermediate to very high risk. The main goal was to check safety, and the study also looked at how many patients achieve…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New drug combo explored for High-Risk blood cancer
Disease control TerminatedThis study tested a new drug called sabatolimab combined with two standard treatments (azacitidine and venetoclax) in 20 adults with high or very high risk myelodysplastic syndrome (MDS) who could not have intensive chemotherapy or a stem cell transplant. The goal was to see if t…
Matched conditions: MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:06 UTC